Category: Press Releases

Empowering the Next Generation: EBC Supports the Legacy of the “One Baht School”

EBC Financial Group reinforces its commitment to Bangkok’s “One Baht School,” providing essential nutrition and care to nearly 2,000 children in slum communities. This initiative reflects EBC’s core mission of “standing by” vulnerable populations through long-term, sustainable support rather than one-time donations. EBC Team Member handling food donations to the

Read more

Empowering the Next Generation: EBC Supports the Legacy of the “One Baht School”

EBC Financial Group reinforces its commitment to Bangkok’s “One Baht School,” providing essential nutrition and care to nearly 2,000 children in slum communities. This initiative reflects EBC’s core mission of “standing by” vulnerable populations through long-term, sustainable support rather than one-time donations. EBC Team Member handling food donations to the

Read more

Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain

ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its two aseptic suites in Valladolid, Spain. The $4 million dollar investment is in accordance with the EU’s GMP Annex 1 standards.

Read more

Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients

Read more

Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients

Read more

Recent News